46th week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110280803 | RADIOIODINATION METHOD - The present invention provides a method for the synthesis of radioiodinated compounds which is advantageous over prior art methods. Using a hydrazine or an aminoxy in place of a primary amine for indirect radioiodination facilitates a much quicker reaction thus reducing reaction time and increasing the yield. In addition, where there are primary amines in the molecule to be radioiodinated, such as the N-terminus of a peptide or lysine residues, reaction at the hydrazine or aminoxy is greatly favoured. | 2011-11-17 |
20110280804 | HIGHLY SELECTIVE SIGMA RECEPTOR RADIOLIGANDS - Compounds having the general formula III′, or IV′ | 2011-11-17 |
20110280805 | NEUROTOXIC STEROL GLYCOSIDES - The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof, in animal models of neurodegenerative disease. Neurotoxicity-modulating chromenols can also be used in these animal models in combination with the neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof. | 2011-11-17 |
20110280806 | DYE CONJUGATE IMAGING AGENTS - The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of dihydrocarbazolium dyes with biological targeting moieties, such as peptides. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. The dihydrocarbazolium dyes are functionalised with water solubilising groups and have functional groups which facilitate conjugation to biological targeting moieties. | 2011-11-17 |
20110280807 | Methods and Models for Stress-Induced Analgesia - The invention disclosed relates to methods and models for enhancing stress-induced analgesia through non-opioid mechanisms. | 2011-11-17 |
20110280808 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins - The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed. | 2011-11-17 |
20110280809 | PDIA4, TARGET OF CYTOPILOYNE DERIVATIVES, FOR TUMOR DIAGNOSIS AND TREATMENT - Methods of diagnosing cancer that are based in part on the findings that Pdia4 promotes cell growth, cell proliferation, and cell cycle are disclosed herein. Methods of using microvessel density as a surrogate marker and reducing tumor microvessel density in a subject are also enclosed herein. | 2011-11-17 |
20110280810 | SURGICAL OPTICAL SYSTEMS FOR DETECTING BRAIN TUMORS - A method of detecting a brain tumor includes administering indocyanine green to a living body; exposing brain tissue in the living body; irradiating the exposed brain tissue with excitation light of indocyanine green; obtaining an image based on fluorescence of the excited indocyanine green in the brain tissue, wherein the image is obtained using an endomicroscope; and identifying portions of the brain tissue corresponding to the brain tumor based on the image. | 2011-11-17 |
20110280811 | METHOD OF MEASURING PROPULSION IN LYMPHATIC STRUCTURES - Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked to provide quantitative information regarding lymph propulsion and function. In particular, lymph flow velocity and pulse frequency may be determined using the disclosed methods. | 2011-11-17 |
20110280812 | FLAVOR-ENHANCING AMIDE COMPOUNDS - The present invention has discovered that amide compounds represented by Formula I set forth below have unexpected and advantageous flavor enhancement and modification properties: | 2011-11-17 |
20110280813 | NEURAMINIDASE INHIBITORS AND USES THEREOF - The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors. | 2011-11-17 |
20110280814 | Process For Making Improved Oral Compositions - Processes for preparing an oral care composition having improved taste, color, odor and/or clarity, wherein said processes comprise the steps of: providing an unfiltered dentifrice component selected from unfiltered alkyl phosphate surfactants, alkyl phosphate ethoxylated surfactants, lauryl sulfate surfactants, betaine surfactants, antibacterial agents, cetyl pyridinium chloride, metal Salts, phytic acids, or mixtures thereof; filtering the unfiltered dentifrice component with an adsorbent to form a filtered dentifrice component; and incorporating the filtered dentifrice component into the oral care composition. In one such process, activated carbon with a median particle size of less than or equal to about 30 μm, optionally a macro-mesoporous:microporous ratio about 0.9 or higher and optionally a BET per Total Volume of equal to or less than about 1600 m̂2/g, has been found to remove undesirable contaminants from oral care dentifrice components, such as alkyl phosphate surfactant, alkyl phosphate ethoxylated surfactant, lauryl sulfate surfactant, betaine surfactants, antibacterial agents, cetyl pyridinium chloride, metal salts, or phytic acid. | 2011-11-17 |
20110280815 | COMPOSITION FOR INHIBITING MELANIN PRODUCTION AND APPLICATION THEREOF - The present invention provides a composition for inhibiting melanin production to promote skin whitening, which is characterized by containing compounds represented by formula (I): | 2011-11-17 |
20110280816 | COMPOSITIONS CONTAINING HYPERBRANCHED POLYOL, ACRYLIC FILM FORMER AND ALKOXYLATED MIXED POLYESTER - The invention relates to a composition, especially a cosmetic composition, comprising at least one hyperbranched polyol, at least one acrylic film forming agent, and at least one alkoxylated mixed polyester, as well as to methods of using such compositions. | 2011-11-17 |
20110280817 | COMPOSITIONS CONTAINING HYPERBRANCHED POLYOL AND ACRYLIC FILM FORMER - The invention relates to a composition, especially a cosmetic composition, comprising at least one hyperbranched polyol and at least one acrylic film forming agent, as well as to methods of using such compositions. | 2011-11-17 |
20110280818 | COMPOSITIONS CONTAINING HYPERBRANCHED POLYOL AND TACKIFIER - The invention relates to a composition, especially a cosmetic composition, comprising at least one hyperbranched polyol and at least one tackifier, as well as to methods of using such compositions. | 2011-11-17 |
20110280819 | WASHABLE EYE MAKEUP COMPOSITION HAVING WATERPROOF AND SMUDGE-RESISTANT PROPERTIES - The present invention is directed to a washable eye makeup composition having waterproof and smudge-resistant properties containing: (a) at least one oil-soluble polar modified polymer; (b) at least one polyamine; (c) at least one alkyl ethoxylated polymer wax; (d) water; (e) at least one non-volatile solvent capable of solubilising the polar modified polymer; (e) at least one volatile solvent; and (f) optionally, at least one colorant. | 2011-11-17 |
20110280820 | LONG-WEAR, WATERPROOF MASCARA COMPOSITION - The present invention is directed to a long wear, waterproof eye makeup composition having a creamy texture and feel containing: (a) at least one polyamine; (b) an oil-soluble polar modified polymer; (c) water; (d) at least one non-volatile oil capable of solubilizing the oil-soluble polar modified polymer; (d) at least one volatile solvent; (e) at least one wax, and (f) optionally, at least one colorant, wherein the composition does not require a surfactant/emulsifier or can be surfactant- or emulsifier-free. | 2011-11-17 |
20110280821 | HAIR CARE SOLUTION FORMING A FILM PROTECTING NATURAL HAIR FROM GLUING PRODUCTS - The hair gluing product of the invention is gel or crystallizing protective growth serum that dries down to form a film over your natural hair and scalp. The invention allows for application of hair bonding glue without damaging natural hair or scalp. It contains aloe extract, tea tree oil, chamomile extract. It is available in an assortment of colors. The purpose of the gel or serum is to protect client's natural hair/scalp from being damaged by the use of hair bonding glue, which is used for weaving styles. When hair bonding glue is applied directly to the natural hair and scalp it has a tendency to cause breakage and leads to damage hair the invention will cover the natural hair, which will allow the hair bonding glue to be applied directly to the shield that appears after the invention dries on the hair/scalp. | 2011-11-17 |
20110280822 | Structured surfactant system - An aqueous structured surfactant composition contains an anionic surfactant selected from isethionate surfactants, taurate surfactants, and sarcosinate surfactants, and mixtures thereof, and an electrolyte and is useful in personal care applications. | 2011-11-17 |
20110280823 | COMPOSITION - Concentrated shampoo composition comprising from 32 to 38% wt. cleansing surfactant and from 0.5 to 3% wt. coconut oil or palm kernel oil and wherein the composition has a zero shear viscosity of from 2 to 2000 Pa·s and comprises 90% vol. or more composition in the nematic discotic phase. | 2011-11-17 |
20110280824 | Furanone Copolymers - The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided. | 2011-11-17 |
20110280825 | EXTRACORPOREAL DEVICES AND METHODS OF TREATING COMPLICATIONS OF PREGNANCY - The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. | 2011-11-17 |
20110280826 | Y-SHAPED POLYETHYLENE GLYCOL MODIFIED G-CSF, THE PREPARATION AND USE THEREOF - The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof. | 2011-11-17 |
20110280827 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES - The invention relates to methods and compositions for treating a subject afflicted with a hematological malignancy using a combination of a CXCR4 antagonist and an immunotherapeutic agent. | 2011-11-17 |
20110280828 | METHODS FOR TREATMENT OF MICROBIAL DISORDERS - The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions. | 2011-11-17 |
20110280829 | Low Molecular Weight Sulphated Polysaccharides as Candidates for Anti-Angiogenic Therapy - Low molecular weight sulphated L-fucose polysaccharide fraction having a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, a fucosis content ranging from 30 and 70% w/w relative to the total weight of the fraction, and a polydispersity index ranging from 1 and 2, wherein the fraction is obtainable by free radical depolymerisation of a crude fucan of vegetal origin; process for manufacturing same; pharmaceutical composition and medicament containing same and their use for inhibiting neovascularisation. | 2011-11-17 |
20110280830 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2011-11-17 |
20110280831 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS - The present invention provides a combination which comprises (a) methotrexate and (b) a non-hepatotoxic DHODH inhibitor of formula (I): wherein: R | 2011-11-17 |
20110280832 | EOTAXIN-2 (CCL24) INHIBITORS IN INFLAMMATORY, AUTOIMMUNE, AND CARDIOVASCULAR DISORDERS - The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. Also provided are specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing such antibodies. | 2011-11-17 |
20110280833 | PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME - Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome. | 2011-11-17 |
20110280834 | METHODS AND COMPOSITIONS FOR CARDIAC TISSUE REGENERATION - Methods for treating an injured cardiac tissue in a subject are provided herein. Methods for improving survival, engraftment and proliferation of stem cells in a cardiac tissue are provided. Also provided are methods for generating cardiac cells. Further provided are compositions for generating cardiac cells in a subject. | 2011-11-17 |
20110280835 | COMMENSAL BACTERIA AS SIGNAL MEDIATORS WITHIN A MAMMALIAN HOST - Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganism to prevent or ameliorate diseases are also provided. The genetically engineered cells or microorganisms can be engineered to express a signal and used to interrupt the signaling-dependent virulence of an invading pathogen. The cells or microorganisms can be used to provide signal-dependent expression of a desirable gene in order to interrupt, prevent, and/or ameliorate a disease of mammals, such as parasitic diseases, infectious diseases, autoimmune diseases and genetic disorders. | 2011-11-17 |
20110280836 | COMPOSITIONS FOR BACTERIAL MEDIATED GENE SILENCING AND METHODS OF USING THE SAME - The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of | 2011-11-17 |
20110280837 | BIFIDOBACTERIUM LONGUM AND HIPPOCAMPAL BDNF EXPRESSION - The present invention relates in general to edible compositions comprising probiotics. One embodiment of the present invention relates to an edible composition comprising | 2011-11-17 |
20110280838 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION USING HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS - Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells and optionally a hydrogel. In some embodiments, administering the cells promotes repair and regeneration of degenerated IVD tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided. | 2011-11-17 |
20110280839 | Entomopathogenic Fungi and Uses Thereof - The present invention provides a strain of entomopathogenic | 2011-11-17 |
20110280840 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA - The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota. | 2011-11-17 |
20110280841 | Electroprocessing in Drug Delivery and Cell Encapsulation - The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances or other compounds, molecules, cells, vesicles. The compositions can be used in substance delivery, including drug delivery within an organism by, for example, releasing substances or containing cells that release substances. The compositions can be used for other purposes, such as prostheses or similar implants. | 2011-11-17 |
20110280842 | METHODS OF REPROGRAMMING CELLS - The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic β-cell. | 2011-11-17 |
20110280843 | TREATMENT OF DISEASES AND DISORDERS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 2011-11-17 |
20110280844 | HEPATOCYTE PRODUCTION BY FORWARD PROGRAMMING - The invention generally features methods for providing hepatocytes from a variety of cell sources, particularly pluripotent stem cells, therapeutic compositions featuring such cells, and methods of using them for the treatment of subjects. | 2011-11-17 |
20110280845 | TREATMENT OF RHEUMATOID ARTHRITIS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 2011-11-17 |
20110280846 | OLFACTORY EPITHELIAL-DERIVED STEM CELLS AND METHODS OF USE THEREFOR - The presently disclosed subject matter provides recombinant dopaminergic neurons and/or recombinant progenitors thereof that include one or more transgenes encoding a nurr-1 polypeptide, a pitx3 polypeptide, an Imxi a polypeptide, a biologically active fragment thereof, a biologically active derivative thereof, and/or any combination thereof. Also provided are methods for producing a recombinant dopaminergic neuron or recombinant progenitor thereof, methods for producing lineage primed cells, methods for ameliorating at least one symptom associated with a neurological disorder, methods for transplantation, methods for inducing growth, repair, and/or regeneration of a neuron, for delivering a cytokine or a growth factor to the central nervous system, methods for providing a dopaminergic neuron function, and cell cultures that include recombinant olfactory epithelial-derived stem cells and/or a differentiated derivatives thereof. | 2011-11-17 |
20110280847 | METHODS AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORE GERMINATION AND OUTGROWTH - Certain bile acids, including novel bile acids, and derivatives thereof can be used to inhibit the germination of | 2011-11-17 |
20110280848 | COMPOSITION COMPRISING CHICORIC ACID AND/OR DERIVATIVES THEREOF - The present invention relates generally to the field of food and drinks. In particular, for example, a composition is provided that allows to provide tartaric and/or caffeic acid to a subject. One embodiment of the present invention is a composition comprising an ingredient containing chicoric acid and/or derivatives thereof, and a lactic acid bacterium capable of hydrolysing chicoric acid and/or derivatives thereof to generate tartaric and/or caffeic acid. | 2011-11-17 |
20110280849 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS - Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide. | 2011-11-17 |
20110280850 | Compositions Containing DNA Repair Enzyme And Anogeissus Extract - A topical composition comprising at least one extract from the | 2011-11-17 |
20110280851 | Compositions Comprising Cranberry Extract and Methods of Use Thereof - Described herein are compositions that comprise cranberry extract and are potent and low in calories. Methods of preventing or treating infections by administering the described compositions are also provided. | 2011-11-17 |
20110280852 | NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE - A composition for treating, ameleliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death includes administering a fatty acid component enriched for one or more activated fatty acids. | 2011-11-17 |
20110280853 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES - Compositions and methods for treating or preventing | 2011-11-17 |
20110280854 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR THE PREVENTION OF E. COLI INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF E. COLI SURFACES - Compositions and methods for treating or preventing | 2011-11-17 |
20110280855 | VITAMIN C COMPOSITIONS - The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives, and at least one ascorbate-glucose transport enhancer in an amount from about 0.01% by weight of actives to about 99.0% by weight of actives. In other aspects, methods of improving the transport of ascorbate into cells and tissues, and improving the ascorbate or antioxidant status of a person, are provided that include providing a composition comprising ascorbate and at least one ascorbate-glucose transport enhancer. | 2011-11-17 |
20110280856 | TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY - The invention provides highly purified α-Gal A, and various methods for purifying it; α-Gal A preparations with altered charge and methods for making those preparations; α-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an α-Gal A preparation to a subject. | 2011-11-17 |
20110280857 | ADVANCED FUNCTIONAL BIOCOMPATIBLE FOAM USED AS A HEMOSTATIC AGENT FOR COMPRESSIBLE AND NON-COMPRESSIBLE ACUTE WOUNDS - A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood. | 2011-11-17 |
20110280858 | TREATMENT OF WOUNDS - The invention generally provides compositions, kits, pharmaceuticals, and methods that promote and enhance wound healing. Such compositions comprise isolated trypsinogen or trypsin polypeptides or isolated polypeptides obtainable from the excretions/secretions (ES) of | 2011-11-17 |
20110280859 | PREVENTING AND TREATING SEPSIS - Provided are polypeptides comprising a variant activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Also provided are nucleic acids encoding the polypeptides, and cells, compositions and kits containing the polypeptides and nucleic acids. Also provided are methods of treating sepsis in a subject comprising administering to the subject one or more of the provided polypeptides or nucleic acids. Methods of screening for polypeptides with enhanced activated protein C and for an agent for treatment of sepsis are provided. Finally, provided is a method of treating sepsis in a subject comprising administering to the subject a pharmaceutical composition comprising one or more RGD-containing peptides. | 2011-11-17 |
20110280860 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES - The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents. | 2011-11-17 |
20110280861 | METHOD FOR MIR-125A IN PROMOTING HEMATOPOIETIC STEM CELL SELF RENEWAL AND EXPANSION - Embodiments of the invention relate to methods and compositions for the expansion of hematopoietic stem cell (HSC) self renewal. The microRNA-125a is a master control of HSC self-renewal. Increased expression of mir-125a increased HSC self-renewal by 6-30 folds. Increased expression of mir-125a can be used to expand HSC ex vivo and in vivo. | 2011-11-17 |
20110280862 | GEP AND DRUG TRANSPORTER REGULATION, CANCER THERAPY AND PROGNOSIS - Described herein are methods for manipulating GEP and/or drug transporters (e.g., ABCB5 and/or ABCF1) on a cell, as well as related products. Also described herein are methods for treating cancer cells using GEP and/or drug transporter and/or their binding molecules and suppression thereof. Methods of cancer treatment targeting the GEP and/or drug transporters, alone or in combination with chemotherapy are also described herein. Also provided herein are sets of markers whose expression patterns can be used to differentiate clinical conditions, such as high or low levels of GEP and drug transporters. Based on the levels of GEP and drug transporters, the likelihood of cancer recurrences, drug sensitivity, and prognosis can be determined. Methods of classifying and treating patients based on the prognosis are also provided herein. | 2011-11-17 |
20110280863 | METHODS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF PREECLAMPSIA - Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia. | 2011-11-17 |
20110280864 | Low Viscosity Highly Concentrated Suspensions - The present invention also provides a high concentration low viscosity suspension of an pharmaceutically acceptable solvent with one or more sub-micron or micron-sized non-crystalline particles comprising one or more proteins or peptides. Optionally one or more additives in the pharmaceutically acceptable solvent to form a high concentration low viscosity suspension with a concentration of at least 20 mg/ml and a solution viscosity of between 2 and 100 centipoise that is suspendable upon shaking or agitation, wherein upon delivery the one or more sub-micron or micron-sized peptides dissolves and do not form peptide aggregates syringeable through a 21 to 27-gauge needle. | 2011-11-17 |
20110280865 | Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof - Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described. | 2011-11-17 |
20110280866 | ANTI-CD 160 MONOCLONAL ANTIBODIES AND USES THEREOF - The present invention concerns an antibody or fragment thereof, capable of binding to CD 160, said antibody comprising a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: (i) the light chain CDR1: QSISNH (SEQ ID NO: 1), (ii) the light chain CDR2: YAS, (iii) the light chain CDR3: QQSNSWPLT (SEQ ID NO: 2), and a light chain framework sequence from an immunoglobulin light chain; and b) a heavy chain comprising three heavy chain complementary regions (CDRs) having the following amino acid sequences: (i) the heavy chain CDR1: GYTFTDYW (SEQ ID NO: 3), (ii) the heavy chain CDR2: IYPGDDDA (SEQ ID NO: 4); (iii) the heavy chain CDR3: ARRGIAAVVGGFDY (SEQ ID NO: 5); and a heavy chain framework sequence from an immunoglobulin heavy chain; a pharmaceutical comprising said antibody and the use of said antibody for preparation of a medicament for treating and/or preventing a pathology associated with endothelial cells proliferation engaged in an angiogenesis process. | 2011-11-17 |
20110280867 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2011-11-17 |
20110280868 | METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTAGONISTS - The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof. | 2011-11-17 |
20110280869 | METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS - The present invention provides to methods of preventing, treating or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof comprising administering to a subject in need thereof one or more CD2 antagonists and at least one other prophylactic or therapeutic agent. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder. | 2011-11-17 |
20110280870 | HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF - Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided. | 2011-11-17 |
20110280871 | METHODS FOR PREVENTION AND TREATMENT OF INFLAMMATION USING ANTI-CHEMOKINE ANTIBODIES - It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines. | 2011-11-17 |
20110280872 | METHODS FOR PREVENTION AND TREATMENT OF INFLAMMATION USING ANTI-CHEMOKINE ANTIBODIES - It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines. | 2011-11-17 |
20110280873 | MCP1-Ig FUSION VARIANTS - The present invention provides, in part, MCP1-Ig fusion polypeptides exhibiting surprisingly beneficial properties as well as methods for treating various diseases (e.g., inflammatory diseases) by administering any of such fusions. | 2011-11-17 |
20110280874 | MODULATING ANGIOGENESIS - Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye. | 2011-11-17 |
20110280875 | ANTIBODIES WHICH BIND HUMAN CXCR3 - Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments. | 2011-11-17 |
20110280876 | MUTATED NETRIN - 4, FRAGMENTS THEREOF AND THEIR USE AS MEDICINES - A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies. | 2011-11-17 |
20110280877 | Inhibition of B7-H1/CD80 interaction and uses thereof - The present invention provides a composition comprising an agent which specifically blocks interaction between B7-H1 and CD80 but not interaction between B7-H1 and PD-1 and a vaccine, optionally in a pharmaceutically acceptable carrier. Further provided is a method of treating or inhibiting abnormal cell proliferation or a viral infection in a host comprising the step of administering an agent which specifically blocks interaction between B7-H1 and CD80 but does not block interaction between B7-H1 and PD-1 in combination with a vaccine against the cancer to a host in need thereof. | 2011-11-17 |
20110280878 | SUBSTANCE SPECIFIC TO HUMAN PD-1 - The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy. | 2011-11-17 |
20110280879 | CHIMERIC PEPTIDES AS IMMUNOGENS, ANTIBODIES THERETO, AND METHODS FOR IMMUNIZATION USING CHIMERIC PEPTIDES OR ANTIBODIES - The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the precursor or mature protein are self molecules. The chimeric peptide or peptides have an end-specific B cell epitope from a naturally-occurring internal peptide cleavage product of a precursor or mature protein, as a free N- or C-terminus, fused with or without spacer residues to a T helper cell epitope derived from a living source different from that of the internal peptide cleavage product. | 2011-11-17 |
20110280880 | PREVENTION, TREATMENT AND DIAGNOSIS OF P.GINGIVALIS INFECTION - The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of | 2011-11-17 |
20110280881 | NOVEL ANTI-HSP90 MONOCLONAL ANTIBODY - [Summary] The present invention relates an anti-HSP90 antibody and use thereof, more specifically to an anti-HSP90 antibody capable of recognizing cell surface HSP90, a vaccine that utilizes the antibody, a drug that utilizes the antibody, an adjuvant comprising the antibody, a method of detecting a cell expressing HSP90 on the cell surface using the antibody, and the like. | 2011-11-17 |
20110280882 | LEUKOLECTINS AND USES THEREOF - The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal. | 2011-11-17 |
20110280883 | FULLY HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES - Disclosed are fully human anti-epidermal growth factor receptor (EGFR) antibodies, fragments thereof, and nucleic acid sequences encoding for the same. Further disclosed are methods of making and using the antibodies. | 2011-11-17 |
20110280884 | ANTI-CD98 ANTIBODY - A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided. | 2011-11-17 |
20110280885 | CANCER IMMUNOTHERAPY - A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2. | 2011-11-17 |
20110280886 | TREATING CANCER BY MODULATING MNK - The present invention relates to a method for treating cancer in a subject using a mTOR inhibitor in combination with a therapeutically effective amount of a modulator of a MNK. | 2011-11-17 |
20110280887 | METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 2011-11-17 |
20110280888 | ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME - The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes. | 2011-11-17 |
20110280889 | HIGH AFFINITY T CELL RECEPTOR AND USE THEREOF - The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen. | 2011-11-17 |
20110280890 | PRODRUGS OF CC-1065 ANALOGS - The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody, and for the therapeutic use of such prodrug and conjugates, and for processes for preparing such prodrugs and conjugates. | 2011-11-17 |
20110280891 | SITE-SPECIFIC ATTACHMENT OF DRUGS OR OTHER AGENTS TO ENGINEERED ANTIBODIES WITH C-TERMINAL EXTENSIONS - The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided. | 2011-11-17 |
20110280892 | TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES - The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins. | 2011-11-17 |
20110280893 | SYNTHETIC LIPID A DERIVATIVE - The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative. | 2011-11-17 |
20110280894 | HER2/NEU SPECIFIC T CELL RECEPTORS - The present invention is directed to T cell receptors (TCR) recognizing antigenic peptides derived from Her2/neu, in particular peptide 369, and being capable of inducing peptide specific killing of a target cell overexpressing HER2/neu. The present invention is further directed to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of HER2/neu. The present invention is further disclosing a method of generating antigen specific T cells. | 2011-11-17 |
20110280895 | IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN - The present invention provides a means to be used for a new immunotherapy of cancer or infection utilizing activation of dendritic cell (DC) by innate immunity, namely, a method of preparing a cell co-expressing a target antigen and CD1d and having an ability to activate immunity against the target antigen, comprising the following steps (a) and (b): | 2011-11-17 |
20110280896 | METHODS AND COMPOSITIONS FOR TUMOR VACCINATION AND THERAPY - The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity. | 2011-11-17 |
20110280897 | POLYPEPTIDES AND USES THEREOF - The invention provides a polypeptide having a sequence comprising from 10 to 24 consecutive amino acids from residues 215-233 of the sequence of human cyclin B1 protein or homolog thereof, as well as a nucleic acid molecule encoding the polypeptide, and compositions thereof. The invention also provides a method for using such polypeptides, nucleic acid molecules, or combinations thereof for treatment or prophylaxis of cancer in patients. | 2011-11-17 |
20110280898 | INHBB EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME - Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from INHBB that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical compositions containing the INHBB polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the INHBB polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. | 2011-11-17 |
20110280899 | Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes - The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope. | 2011-11-17 |
20110280900 | CLOSTRIDIUM CHAUVOEI POLYPEPTIDE, DNA ENCODING THE POLYPEPTIDE AND A VACCINE COMPRISING THE POLYPEPTIDE - The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of | 2011-11-17 |
20110280901 | Diagnosis and treatment of Trypanosoma cruzi infection and chagas disease - Provided herein are vaccine compositions for control of | 2011-11-17 |
20110280902 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more | 2011-11-17 |